# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Stifel analyst Annabel Samimy maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $40 price target.
REGENXBIO Inc. (NASDAQ:RGNX) today announced the publication of results from the Phase I/IIa trial evaluating the safety and to...
HC Wainwright & Co. analyst Yi Chen initiates coverage on Regenxbio (NASDAQ:RGNX) with a Buy rating and announces Price ...
REGENXBIO's promising gene therapy advancements! RBC Capital Markets upgraded REGENXBIO (RGNX), citing impressive RGX-202 t...
RBC Capital analyst Luca Issi upgrades Regenxbio (NASDAQ:RGNX) from Sector Perform to Outperform and raises the price target...
Chardan Capital analyst Daniil Gataulin maintains Regenxbio (NASDAQ:RGNX) with a Buy and maintains $52 price target.